Boehringer submits Pradaxa antidote app; Sanofi's Lantus follow-up nears EMA approval;

> Boehringer Ingelheim has submitted an FDA application for its Pradaxa antidote. Release | More

> The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's ($SNY) Lantus follow-up, Toujeo, for European approval. Report

> India's Natco Pharma is challenging the patent on Gilead's Sovaldi despite its licensing agreement to make and sell cheap versions of the drug. More (sub. req.)

> AstraZeneca ($AZN) has completed its deal for Actavis' ($ACT) North American respiratory portfolio. Brief

And Finally... Millennials aren't big on big purchases--even cars and houses--but they do like to spend money on health and fitness gadgets. Infographic

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.